|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
US4866048A
(en)
|
1985-08-02 |
1989-09-12 |
Leo Pharmaceutical Products Ltd. |
Novel vitamin D analogues
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
GB2265624B
(en)
|
1992-03-31 |
1995-04-19 |
British Tech Group |
17-substituted steroids useful in cancer treatment
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
ES2127413T3
(es)
|
1993-09-30 |
1999-04-16 |
Btg Int Ltd |
Sintesis de esteroides 17-(3-piridilo).
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
CA2255615C
(en)
|
1996-05-22 |
2006-08-29 |
Neuromedica, Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
ES2368824T3
(es)
|
1998-03-27 |
2011-11-22 |
Oregon Health & Science University |
Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
CA2356462A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
JP2003525254A
(ja)
|
2000-03-02 |
2003-08-26 |
ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション |
併用化学療法
|
|
AU2001248849A1
(en)
|
2000-04-24 |
2001-11-07 |
Kyowa Hakko Kogyo Co. Ltd. |
Estra-1,3,5(10)-triene derivatives
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
WO2001087307A2
(en)
|
2000-05-15 |
2001-11-22 |
Celgene Corp. |
Compositions and methods for the treatment of cancer
|
|
WO2001093836A2
(en)
|
2000-06-09 |
2001-12-13 |
Teni Boulikas |
Encapsulation of polynucleotides and drugs into targeted liposomes
|
|
WO2002003286A1
(en)
|
2000-07-05 |
2002-01-10 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
DE60113286T2
(de)
|
2000-10-17 |
2006-06-22 |
Merck & Co., Inc. |
Oral aktive salze mit tyrosinkinaseaktivität
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
AU2002219472A1
(en)
|
2001-01-02 |
2002-07-16 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
ATE413175T1
(de)
|
2001-04-18 |
2008-11-15 |
Euro Celtique Sa |
Spiroinden- und spiroindan-verbindungen
|
|
NZ528978A
(en)
|
2001-04-18 |
2004-06-25 |
Euro Celtique S |
Spiropyrazole compounds
|
|
ATE434607T1
(de)
|
2001-04-18 |
2009-07-15 |
Euro Celtique Sa |
1-(4-amino-cyclohexyl)-1,3-dihydro-2h- benzimidazole-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz
|
|
DE60235274D1
(de)
|
2001-04-18 |
2010-03-18 |
Euro Celtique Sa |
Octahydrobenzimidazolon-Verbindungen als Analgetika
|
|
WO2002091993A2
(en)
|
2001-05-10 |
2002-11-21 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2004016753A2
(en)
|
2002-08-15 |
2004-02-26 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20040171630A1
(en)
|
2001-06-19 |
2004-09-02 |
Yuntae Kim |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
WO2003020699A2
(en)
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
ES2276950T3
(es)
|
2001-09-06 |
2007-07-01 |
Schering Corporation |
Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1444209A4
(en)
|
2001-11-07 |
2005-02-16 |
Merck & Co Inc |
INHIBITORS OF MITOTIC KINESINS
|
|
WO2003050064A2
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
DE60332316D1
(de)
|
2002-02-01 |
2010-06-10 |
Euro Celtique Sa |
2-piperazinpyridine für die schmerzbehandlung
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
AU2003211877A1
(en)
|
2002-03-11 |
2003-09-22 |
Takeda Chemical Industries, Ltd. |
Remedies for sex hormone-dependent disease
|
|
US7273869B2
(en)
|
2002-04-08 |
2007-09-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
DE60318198T2
(de)
|
2002-05-02 |
2008-12-04 |
Merck & Co., Inc. |
Tyrosinkinase-hemmer
|
|
CA2486215A1
(en)
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
AU2003247829A1
(en)
|
2002-06-28 |
2004-01-19 |
Euro-Celtique, S.A. |
Therapeutic piperazine derivatives useful for treating pain
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
KR20050057086A
(ko)
|
2002-08-28 |
2005-06-16 |
홀리스-에덴 파마슈티칼즈, 인코포레이티드 |
치료적 처치 방법
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
AU2003274823A1
(en)
|
2002-10-23 |
2004-05-13 |
Pantarhei Bioscience B.V. |
Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
|
|
EP1558609A4
(en)
|
2002-10-30 |
2008-05-28 |
Merck & Co Inc |
KINASE INHIBITORS
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
WO2004060488A1
(en)
|
2002-12-17 |
2004-07-22 |
Schering Corporation |
17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
WO2004062620A2
(en)
|
2003-01-13 |
2004-07-29 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
EP1633316A4
(en)
|
2003-05-06 |
2008-04-02 |
Human Genome Sciences Inc |
ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
CN1856484B
(zh)
|
2003-07-24 |
2010-09-22 |
欧洲凯尔蒂克公司 |
用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
|
|
EP1867644B1
(en)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
HRP20100229T1
(hr)
|
2003-08-01 |
2010-05-31 |
Euro-Celtique S.A. |
Terapeutski agensi korisni za liječenje boli
|
|
WO2005021487A1
(en)
|
2003-08-27 |
2005-03-10 |
Merck Frosst Canada Ltd. |
Cathepsin inhibitors
|
|
JP4634385B2
(ja)
|
2003-09-22 |
2011-02-16 |
ユーロ−セルティーク エス．エイ． |
疼痛の治療に有用なフェニル−カルボキサミド化合物
|
|
DE602004017481D1
(de)
|
2003-09-22 |
2008-12-11 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
|
EP1673092B1
(en)
|
2003-10-17 |
2007-08-15 |
4 Aza Ip Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
US7445794B1
(en)
|
2004-04-29 |
2008-11-04 |
The Regents Of The University Of Colorado |
Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
AU2005281797B2
(en)
|
2004-09-10 |
2011-07-07 |
Jagotec Ag |
Tablets with site and time-controlled gastrointestinal release of active ingredient
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
KR20080018874A
(ko)
|
2005-04-27 |
2008-02-28 |
유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. |
인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
|
|
EP1877060A2
(en)
|
2005-04-28 |
2008-01-16 |
The Regents of the University of Colorado |
Therapeutic bifunctional compounds
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
|
EP2007733B1
(en)
|
2006-04-03 |
2016-05-25 |
MSD Italia S.r.l. |
Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
|
|
AU2007300734A1
(en)
|
2006-06-02 |
2008-04-03 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RNA nanoparticles and nanotubes
|
|
US20080004286A1
(en)
|
2006-06-30 |
2008-01-03 |
Schering Corporation |
Method of Using Substituted Piperidines that Increase P53 Activity
|
|
WO2008005268A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
RS52956B
(sr)
|
2006-08-25 |
2014-02-28 |
Janssen Oncology Inc. |
Kompozicije za tretman kancera
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
US20100168228A1
(en)
|
2006-10-13 |
2010-07-01 |
Reliance Life Sciences Pvt. Ltd. |
Novel chemotherapeutic agents against inflammation and cancer
|
|
DK2805945T3
(da)
|
2007-01-10 |
2019-07-15 |
Msd Italia Srl |
Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
|
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
US20090124587A1
(en)
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
ES2548131T3
(es)
|
2008-01-08 |
2015-10-14 |
Merck Sharp & Dohme Limited |
Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
|
|
WO2009123971A1
(en)
|
2008-03-31 |
2009-10-08 |
Genentech, Inc. |
Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
|
|
EP3067352A3
(en)
|
2008-05-07 |
2016-10-19 |
Cardioxyl Pharmaceuticals Inc. |
Novel nitroso compounds as nitroxyl donors and methods of use thereof
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
JP5804395B2
(ja)
|
2011-02-03 |
2015-11-04 |
ポップ テスト オンコロジー エルエルシー |
診断と治療のためのシステムおよび方法
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
ES2836424T3
(es)
*
|
2012-09-26 |
2021-06-25 |
Aragon Pharmaceuticals Inc |
Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
US9797771B2
(en)
|
2013-03-21 |
2017-10-24 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
SG11201600525XA
(en)
*
|
2013-08-12 |
2016-02-26 |
Tokai Pharmaceuticals Inc |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
WO2015164586A1
(en)
|
2014-04-23 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Targeting parp1 for treatment of tsc and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
WO2016094391A1
(en)
|
2014-12-08 |
2016-06-16 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
|
US9598459B2
(en)
|
2015-08-03 |
2017-03-21 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
PE20190403A1
(es)
|
2016-07-29 |
2019-03-13 |
Janssen Pharmaceutica Nv |
Metodos para tratar el cancer de prostata
|
|
US11040037B2
(en)
|
2016-10-04 |
2021-06-22 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
|
KR20200068689A
(ko)
|
2017-10-11 |
2020-06-15 |
얀센 온콜로지 인크 |
안드로겐 박탈 요법과 함께 아비라테론 아세테이트 + 프레드니손을 투여하여 전립선암을 치료하는 방법
|